Presentation TCT 2017 Prospective, Controlled, Clinical Randomized Trial Evaluating Novel, Microcrystalline and Biodegradable Polymer Paclitaxel Coated Balloon for the Treatment of Femoro-popliteal Disease (The BIOPAC trial) - One Year Outcome Presenter: Mahmood K. Razavi, Krishna J. Rocha-Singh, Piotr P. Buszman November 01, 2017
Presentation TCT 2017 24-month Results From a First-In-Human Data on the Paclitaxel Drug Coated Chocolate Coronary PTCA Balloon Catheters in De-Novo Coronary Lesions Presenter: Emmanouil S. Brilakis, Christopher E. Buller, Georgios Bouras November 01, 2017
Presentation 10-Year Clinical Outcome After Randomization to Sirolimus- or Paclitaxel-Eluting Coronary stents February 13, 2017
Presentation TCT 2016 Multicenter Global Registry Report of the Two-year Outcomes with a Paclitaxel-Coated Balloon in Patients with Complex Femoropopliteal Lesions Presenter: Thomas F. Luscher, Patrick W. Serruys, D. Christopher Metzger October 31, 2016
Presentation CCVVC 2016 Pathology of Drug Eluting Technologies: Are There Differences? Presenter: Renu Virmani June 15, 2016
Presentation Paclitaxel-Coated Balloon in Infrapopliteal Arteries Presenter: Thomas Zeller October 23, 2015
Presentation Late Restenosis After Paclitaxel-Coated Balloon Angioplasty in Patients With DES Restenosis Presenter: Seiji Habara June 30, 2015
Presentation Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease Presenter: Kenneth Rosenfield June 25, 2015
Presentation Long-term Efficacy and Safety of Paclitaxel-Eluting Balloon (PEB) for the Treatment of DES Restenosis Presenter: Sebastian Kufner June 02, 2015
Presentation Paclitaxel-Coated Balloon Catheter Compared With DES for DES Restenosis in Routine Clinical Practice Presenter: S Habara March 01, 2015
Presentation Stent Coverage and Neointimal Proliferation in BMS Postdilated With a Paclitaxel-Eluting Balloon vs EES Presenter: T.C. Poerner December 14, 2014
Presentation TCT 2014 Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Freek Nijhoff September 16, 2014
Presentation TCT 2014 Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters Presenter: Charisse Ward September 16, 2014
Presentation TCT 2014 RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso September 14, 2014
Presentation TCT 2014 TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Yelin Zhao September 13, 2014
Presentation EuroPCR 2014 Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results Presenter: Hiroyoshi Yokoi May 21, 2014
Presentation EuroPCR 2014 BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions Presenter: Jos? Ram?n L?pez-M?nguez May 20, 2014
Presentation TCT 2013 Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development Presenter: Michael Joner October 31, 2013
Presentation TCT 2013 LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries Presenter: Kenneth Rosenfield October 30, 2013
Presentation TCT 2013 RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty vs. Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis Presenter: Fernando Alfonso October 30, 2013